Document Detail


Zygomycosis (mucormycosis): emerging clinical importance and new treatments.
MedLine Citation:
PMID:  15640705     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: New importance has been given to zygomycosis, as what was uncommon is no longer. Zygomycosis (mucormycosis) typically occurs in patients with leukemia, with solid-organ transplants or bone marrow transplants, with diabetic ketoacidosis, in those who have received steroids or are neutropenic, and after desferioxamine therapy. Often, both diagnostic and therapeutic measures are performed too late and are inadequate. Mortality rates may be as high as 80% in infected transplant recipients. Zygomycosis also appears to have made a subtle increase in incidence: up to 8% in autopsied patients with leukemia, and 2% in allogenic bone marrow transplant patients. Most infections are acquired by inhalation, ingestion, or trauma. They rapidly infarct blood vessels, resulting in necrosis of surrounding tissue. Over the past few years, new diagnostic procedures, susceptibility tests, and drugs have entered the clinic, and these advances are discussed in the review. RECENT FINDINGS: With the rise in number of cases of 'zygomycosis', new scrutiny has been directed at the terms 'zygomycosis' and 'mucormycosis'. This review explains their differences and the attending relevance for the clinician. Diagnostic methods include new molecular detection assays and new susceptibility testing options. New treatment options will soon exist with triazole antifungal agents. The first one expected to enter clinical practice is posaconazole in 2005. Its metabolism, pharmacokinetics, in-vitro and in-vivo activity, and clinical study results are described. Finally, we present our approach to zygomycosis. SUMMARY: This review discusses key elements to laboratory diagnostic and susceptibility procedures and new treatment options.
Authors:
Richard N Greenberg; Lauren J Scott; Heather H Vaughn; Julie A Ribes
Related Documents :
15271395 - Imatinib therapy in chronic myeloid leukemia.
2656115 - Aspergillus pancarditis following bone marrow transplantation for chronic myelogenous l...
16434375 - Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant pat...
15005255 - Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced ...
8758345 - Diagnosis and treatment of acute focal bacterial nephritis.
2052975 - Acute anuric renal failure after pigmy rattlesnake bite.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in infectious diseases     Volume:  17     ISSN:  0951-7375     ISO Abbreviation:  Curr. Opin. Infect. Dis.     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2005-01-10     Completed Date:  2005-06-16     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8809878     Medline TA:  Curr Opin Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  517-25     Citation Subset:  IM    
Affiliation:
Medicine Service, Department of Veterans Affairs Medical Center, University of Kentucky College of Medicine, Lexington, Kentucky 40536-0084, USA. mgree01@email.uky.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antifungal Agents / therapeutic use*
Fungi / drug effects*,  isolation & purification
Humans
Zygomycosis / diagnosis*,  drug therapy*
Chemical
Reg. No./Substance:
0/Antifungal Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of real-time fungal susceptibility on clinical practices.
Next Document:  Management of rare fungal infections.